P0192 – Benefit-risk of ofatumumab in treatment-naïve early relapsing multiple sclerosis patients
J. Gartner. Presentation NumberP0192Presentation TopicClinical TrialsLecture Time08:00 – 08:00
Will they, won’t they….they will have the brain atrophy data will it be presented?
Will they Report B cell subsets?
We have had the ozanimod data published, will it be the same at ECTRIMS 2020 and what will the posenimod show what is going to happen?
P0210 – Elezanumab in patients with different disease courses of multiple sclerosis: study design and baseline analysis from two phase 2 studies
Will it won’t it…this is a trial of a repair agent!!